Literature DB >> 27374472

Essential content of evidence-based clinical practice guidelines for bladder cancer: The Japanese Urological Association 2015 update.

Yoshinobu Kubota1, Noboru Nakaigawa1.   

Abstract

The Japanese Urological Association revised the clinical practice guidelines for bladder cancer in April 2015. This was the first update carried out in the 6 years since the development of the initial clinical practice guidelines for bladder cancer in 2009. The descriptive content was revised, and additions were made with a focus on new-found evidence and advances in the latest medical practices, and on the basis of the increasingly aging population observed in the underlying social context in Japan. An algorithm for the treatment of bladder cancer has been presented as a new trial. In the present article, we will introduce the essential contents and clinical questions that address the present revisions.
© 2016 The Japanese Urological Association.

Entities:  

Keywords:  Japanese Urological Association; bladder cancer; clinical practice guideline; treatment algorithm

Mesh:

Year:  2016        PMID: 27374472     DOI: 10.1111/iju.13141

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  15 in total

1.  Are there any metastases to the chest in non-muscle-invasive bladder cancer patients on follow-up computed tomography?

Authors:  Hiroshi Juri; Mitsuhiro Koyama; Haruhito Azuma; Yoshifumi Narumi
Journal:  Int Urol Nephrol       Date:  2018-08-16       Impact factor: 2.370

2.  Oncologic outcomes for open and laparoscopic radical nephroureterectomy in patients with upper tract urothelial carcinoma.

Authors:  Koichi Kido; Shingo Hatakeyama; Naoki Fujita; Hayato Yamamoto; Yuki Tobisawa; Tohru Yoneyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Takuya Koie; Ikuya Iwabuchi; Masaru Ogasawara; Toshiaki Kawaguchi; Chikara Ohyama
Journal:  Int J Clin Oncol       Date:  2018-02-12       Impact factor: 3.402

3.  Myasthenia gravis with myositis induced by pembrolizumab therapy in a patient with metastatic urothelial carcinoma.

Authors:  Nozomi Hayakawa; Eiji Kikuchi; Shigeaki Suzuki; Mototsugu Oya
Journal:  Int Cancer Conf J       Date:  2020-03-21

4.  Single Short Retention Instillation of Pirarubicin Prevents Intravesical Recurrence of Low-risk Non Muscle Invasive Bladder Cancer.

Authors:  Susumu Kageyama; Koki Maeda; Shigehisa Kubota; Tetsuya Yoshida; Takashi Osafune; Yutaka Arai; Hiroki Soga; Zenkai Nishikawa; Yuji Sakano; Keita Takimoto; Chul Jang Kim; Tokuhiro Chano; Akihiro Kawauchi
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

5.  Intravesical bacillus Calmette-Guerin therapy after second transurethral resection for primary T1 bladder cancer.

Authors:  Masato Baba; Susumu Kageyama; Tetsuya Yoshida; Ryo Fujiwara; Chul Jang Kim; Keita Takimoto; Masayuki Nagasawa; Hiroki Soga; Yukihiro Nagatani; Zenkai Nishikawa; Akihiro Kawauchi
Journal:  Int J Clin Oncol       Date:  2018-05-14       Impact factor: 3.402

6.  Detecting asymptomatic recurrence after radical nephroureterectomy contributes to better prognosis in patients with upper urinary tract urothelial carcinoma.

Authors:  Hirotaka Horiguchi; Shingo Hatakeyama; Go Anan; Yuka Kubota; Hirotake Kodama; Masaki Momota; Koichi Kido; Hayato Yamamoto; Yuki Tobisawa; Tohru Yoneyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Takuya Koie; Hiroyuki Ito; Kazuaki Yoshikawa; Toshiaki Kawaguchi; Makoto Sato; Chikara Ohyama
Journal:  Oncotarget       Date:  2018-01-04

7.  Presence of transient hydronephrosis immediately after surgery has a limited influence on renal function 1 year after ileal neobladder construction.

Authors:  Takuma Narita; Shingo Hatakeyama; Takuya Koie; Shogo Hosogoe; Teppei Matsumoto; Osamu Soma; Hayato Yamamoto; Tohru Yoneyama; Yuki Tobisawa; Takahiro Yoneyama; Yasuhiro Hashimoto; Chikara Ohyama
Journal:  BMC Urol       Date:  2017-08-31       Impact factor: 2.264

Review 8.  Asymptomatic recurrence detection and cost-effectiveness in urothelial carcinoma.

Authors:  Hiromichi Iwamura; Shingo Hatakeyama; Makoto Sato; Chikara Ohyama
Journal:  Med Oncol       Date:  2018-05-09       Impact factor: 3.064

9.  Preoperative chronic kidney disease predicts poor oncological outcomes after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma.

Authors:  Hirotake Kodama; Shingo Hatakeyama; Naoki Fujita; Hiromichi Iwamura; Go Anan; Ken Fukushi; Takuma Narita; Toshikazu Tanaka; Yuka Kubota; Hirotaka Horiguchi; Masaki Momota; Koichi Kido; Teppei Matsumoto; Osamu Soma; Itsuto Hamano; Hayato Yamamoto; Yuki Tobisawa; Tohru Yoneyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Takuya Koie; Hiroyuki Ito; Kazuaki Yoshikawa; Atsushi Sasaki; Toshiaki Kawaguchi; Makoto Sato; Chikara Ohyama
Journal:  Oncotarget       Date:  2017-08-24

10.  Trends in neoadjuvant chemotherapy use and oncological outcomes for muscle-invasive bladder cancer in Japan: a multicenter study.

Authors:  Go Anan; Shingo Hatakeyama; Naoki Fujita; Hiromichi Iwamura; Toshikazu Tanaka; Hayato Yamamoto; Yuki Tobisawa; Tohru Yoneyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Takuya Koie; Hiroyuki Ito; Kazuaki Yoshikawa; Toshiaki Kawaguchi; Makoto Sato; Chikara Ohyama
Journal:  Oncotarget       Date:  2017-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.